



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: ATB-346

产品别名: ATB-346

生物活性:

Description	ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity. IC50 value: Target: COX-2 ATB-346 suppressed gastric prostaglandin E(2) synthesis as effectively as naproxen, but produced negligible damage in the stomach and intestine, Unlike naproxen and celecoxib, ATB-346 accelerated healing of pre-existing gastric ulcers. In a mouse airpouch model, ATB-346 suppressed cyclooxygenase-2 activity and inhibited leukocyte infiltration more effectively than naproxen. ATB-346 was as effective as naproxen in adjuvant-induced arthritis in rats, with a more rapid onset of activity. Unlike naproxen, ATB-346 did not elevate blood pressure in hypertensive rats [1]. Treatment with ATB-346 exhibited a significantly more rapid and sustained recovery of motor function, achieving greater than double the increase in locomotion score of the naproxen group by the 10th day of treatment. ATB-346 also significantly reduced the severity of inflammation (proinflammatory cytokines, apoptosis of neural tissue, and nitrosative stress) that characterized the secondary effects of SCI [2].																																			
	<p>In Vitro:</p> <p>DMSO : $\geq 51.6 \text{ mg/mL}$ (141.20 mM)</p> <p>* "\geq" means soluble, but saturation unknown.</p> <table border="1" data-bbox="450 1096 1352 1298"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent</th><th>Mass</th><th>Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>1 mM</td><td></td><td></td><td>2.7364 mL</td><td>13.6818 mL</td><td>27.3635 mL</td></tr><tr><td></td><td>5 mM</td><td></td><td></td><td>0.5473 mL</td><td>2.7364 mL</td><td>5.4727 mL</td></tr><tr><td></td><td>10 mM</td><td></td><td></td><td>0.2736 mL</td><td>1.3682 mL</td><td>2.7364 mL</td></tr></tbody></table>	Preparing Stock Solutions	Solvent	Mass	Concentration	1 mg	5 mg	10 mg									1 mM			2.7364 mL	13.6818 mL	27.3635 mL		5 mM			0.5473 mL	2.7364 mL	5.4727 mL		10 mM			0.2736 mL	1.3682 mL	2.7364 mL
Preparing Stock Solutions	Solvent		Mass	Concentration	1 mg	5 mg	10 mg																													
	1 mM			2.7364 mL	13.6818 mL	27.3635 mL																														
	5 mM			0.5473 mL	2.7364 mL	5.4727 mL																														
	10 mM			0.2736 mL	1.3682 mL	2.7364 mL																														
Solvent&Solubility	<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用, -20°C 储存时,请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline</p> <p>Solubility: $\geq 2.5 \text{ mg/mL}$ (6.84 mM); Clear solution</p> <p>此方案可获得 $\geq 2.5 \text{ mg/mL}$ (6.84 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀。向上述体系中加入 50 μL Tween-80, 混合均匀;然后继续加入 450 μL 生理盐水定容至 1 mL。</p>																																			
	[1]. De Cicco P, et al. ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo. <i>Pharmacol Res.</i> 2016																																			



上海源叶生物科技有限公司
Shanghai yuanYe Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

References

Dec;114:67-73.

[2]. Campolo M, et al. A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. FASEB J. 2013 Nov;27(11):4489-99.



源叶生物